Core Viewpoint - QIAGEN is committed to achieving solid profitable growth through 2028, targeting approximately 7% compound annual sales growth (CAGR) at constant exchange rates and aiming for at least a 31% adjusted operating income margin by 2028 [1][4][13]. Group 1: Financial Targets and Growth Strategy - QIAGEN plans to return at least $1 billion to shareholders from 2024 to 2028, excluding value-creating M&A opportunities [4][16]. - The company aims for at least $2 billion in combined annual sales from its growth pillars by 2028, supported by new product launches and significant investments [7]. - QIAGEN has a goal to achieve at least a 31% adjusted operating income margin by 2028, driven by efficiency initiatives and digitization [13][14]. Group 2: Product Development and Innovation - QIAGEN is focusing on the QIAcuity digital PCR system, planning to triple the number of sales specialists and launch over 100 new assays, with regulatory clearance for clinical use expected in 2024 [7]. - The company confirmed plans for new panels for syndromic diagnosis, including submissions for meningitis and other conditions by 2028 [8]. - QIAGEN Digital Insights will see at least nine new product launches by 2028, with a 40% expansion in the commercial team [9][10]. Group 3: Operational Efficiency and Digitization - QIAGEN is implementing initiatives to streamline its portfolio and improve operational margins, including the discontinuation of the NeuMoDx system [14]. - The company is pursuing about 30 AI initiatives to enhance growth and profitability [14]. - Plans include upgrading the SAP enterprise resource system to simplify organizational processes [14]. Group 4: Leadership and Corporate Responsibility - QIAGEN emphasizes the importance of a strong culture among its 6,000 employees, focusing on empowerment and accountability to achieve its 2028 targets [17]. - The company reaffirms its commitment to ESG goals, including a target to reach net zero carbon emissions by 2050 [17].

Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels and higher test volumes. The latest version of QCI Interpret introduces ...

Venlo, the Netherlands, June 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2023 Sustainability Report which underscores the company's commitment to Environmental, Social, and Governance (ESG) principles, highlighting substantial achievements in its sustainability journey. "In line with our vision of making improvements in life possible, we are committed to delivering the best possible portfolio of products and services while leaving the smallest possible ...

"In line with our vision of making improvements in life possible, we are committed to delivering the best possible portfolio of products and services while leaving the smallest possible footprint on our planet. From whom we source to how we produce, we approach each step with the intention of doing so in a sustainable way. Investing in sustainable practices is not only a moral duty but also a strategic business decision that brings value to our stakeholders, including customers and employees," said Thierry ...

In addition to the product showcase, QIAGEN will present a poster on "Improved Extraction of Total Nucleic Acid from Microbiome Samples". This research highlights advancements in the extraction of DNA and RNA from human microbiome samples, focusing on methods that remove inhibitors and yield higher quality and quantity of nucleic acids. The findings underscore the importance of mechanical lysis using bead beating for efficient, unbiased extraction suitable for automation and standardization across laborator ...

The latest developments aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience. This is also likely to boost QIAGEN's Life Science business area. Image Source: Zacks Investment Research Additional enhancements of the GeneGlobe research platform have been launched recently or are currently in development, including more user-friendly design pages that simplify product selection and a new too ...

Core Viewpoint - QIAGEN has decided to discontinue the NeuMoDx 96 and 288 Molecular Systems due to changing market dynamics post-COVID-19 and evolving customer needs for integrated PCR-based clinical molecular testing systems [1][11]. Company Overview - QIAGEN is a leading global provider of Sample to Insight solutions, enabling customers to gain molecular insights from biological samples. The company offers technologies for isolating and processing DNA, RNA, and proteins, along with bioinformatics software and automation solutions [5]. Financial Outlook - QIAGEN has reaffirmed its Q2 2024 outlook for net sales of at least $495 million at constant exchange rates (CER) and adjusted diluted EPS of $0.52 CER [11]. - The company has updated its full-year 2024 outlook for adjusted diluted EPS to at least $2.14 CER, up from a prior estimate of at least $2.10 CER [8]. Restructuring and Charges - QIAGEN expects to incur a pre-tax restructuring charge of approximately $400 million, primarily in Q2 2024. This includes about $300 million in non-cash items and cash charges related to commitments to customers and suppliers, severance payments, and other obligations [12]. - The restructuring charge will predominantly consist of approximately $90 million for inventory and about $210 million for long-term assets, including around $120 million for acquired intellectual property [12]. Customer Support and Transition - QIAGEN will continue to support existing NeuMoDx users during a transition period into 2025, providing maintenance, technical support, and necessary consumables [2]. - The company is engaging with NeuMoDx customers to discuss the implications of the discontinuation on the 2024 sales forecast, which is estimated at least $55 million CER [8]. Strategic Focus - The decision to discontinue the NeuMoDx systems allows QIAGEN to refocus resources on developing and commercializing other innovative solutions, particularly the QIAstat-Dx system, QIAcuity digital PCR systems, and QIAGEN Digital Insights bioinformatics business [7].

Core Viewpoint - QIAGEN has decided to discontinue the NeuMoDx 96 and 288 Molecular Systems due to changing market dynamics post-COVID-19 and evolving customer needs for integrated PCR-based clinical molecular testing systems [1][2] Company Strategy - The decision reflects QIAGEN's commitment to focus on developing profitable leadership positions and reallocating resources to other areas of its portfolio [2][10] - QIAGEN plans to enhance its offerings in the QIAstat-Dx system for syndromic testing, the QIAcuity digital PCR systems, and the QIAGEN Digital Insights bioinformatics business [10] Financial Outlook - QIAGEN has reaffirmed its Q2 2024 outlook for net sales of at least $495 million at constant exchange rates and adjusted diluted EPS of $0.52 [2] - For the full year 2024, the company has updated its outlook for adjusted diluted EPS to at least $2.14, up from a prior estimate of at least $2.10 [11] Restructuring and Charges - The company expects to incur a pre-tax restructuring charge of approximately $400 million, primarily in Q2 2024, which includes about $300 million in non-cash items [12] - The restructuring charge will consist of approximately $90 million for inventory and about $210 million for long-term assets, including $120 million for acquired intellectual property [12] Customer Support - QIAGEN will continue to support existing NeuMoDx users during the transition period into 2025, providing maintenance, technical support, and necessary consumables [4]

Genetic research is moving fast, and new target genes are rapidly evolving that are not covered by standard or pre-designed assays. To keep pace and close the need gap, the new digital PCR Custom Assay Design Tool has been developed as an interface on the GeneGlobe platform. It enables customers to design and order assays for use on QIAGEN's digital PCR platform QIAcuity outside of QIAGEN's comprehensive catalog of over 200 wet-lab validated assays for copy number variations profiling in translational cance ...

QIAGEN N.V. (QGEN) announced the launch of QIAstat-Dx Gastrointestinal Panel 2 in the United States following the recent FDA clearance of the syndromic test for use in clinical settings. The launch marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis. The latest development from QIAGEN addresses the major challenges of the diagnosis of overlapping symptoms and laborious testing methods in treating GI infections. This should also strengthen th ...